Does Estrogen Cause Breast Cancer? Dr. Felice Gersh on Hormone Therapy, and Risk.

5 Oct 2026 · 65 min
1:05:19

In this hour‑long interview, host Lori Esarey (a breast‑cancer survivor and APRN) and Dr. Felice Gersh, a board‑certified OB‑GYN and integrative‑medicine specialist, discuss whether estrogen causes breast cancer and how hormone therapy (HT) should be used in menopause and after a breast‑cancer diagnosis. The conversation begins with personal stories, then moves into a detailed analysis of the types of hormones used in past studies (conjugated equine estrogen and medroxyprogesterone acetate) versus human‑identical (bioidentical) estradiol and progesterone. Dr. Gersh explains that the Women’s Health Initiative (WHI) examined non‑physiologic hormones, which produced a modest, statistically borderline increase in breast‑cancer risk, while later studies (e.g., the French E3N cohort) found neutral or even reduced risk with bioidentical, cyclic regimens. They clarify that estrogen‑receptor‑positive (ER⁺/PR⁺) tumors are actually a favorable prognostic sign, not evidence that estrogen caused the cancer. Mechanistic pathways are explored: estrogen’s role in reducing inflammation, down‑regulating aromatase, promoting cell cohesiveness, supporting mitochondrial health, and preventing senescent “zombie” cells, all of which may lower metastatic potential. The discussion expands to metabolic health, emphasizing that obesity, visceral fat, insulin resistance, and chronic inflammation drive aromatase activity and estrone production, which can fuel tumor growth. Dr. Gersh stresses that hormones are “life hormones” essential for metabolic homeostasis, bone health, immune regulation, and brain function, and that optimal HT should begin in perimenopause, be physiologically dosed, and be combined with a healthy lifestyle. Lifestyle is framed as the “rim” of a 1,000‑piece puzzle, with hormones as the central pieces; diet, exercise, sleep, stress management, vagal tone, and psychosocial support are presented as indispensable. Clinical decision‑making after a breast‑cancer diagnosis is addressed: data are observational and conflicting, but Dr. Gersh suggests that abrupt cessation of HT may be unnecessary for many women, especially those with low‑grade or in‑situ disease, while acknowledging the lack of definitive trials. The interview concludes with Dr. Gersh’s personal testimony that early, optimized hormone replacement has been the most impactful factor for her own longevity and vitality.

Chapters

More from Lori

0:34
youtube.com

Estrogen, Progesterone & GLP-1: The Hormone Connection

1w ago
1:13
youtube.com

Unlock Muscle Mass Your Guide to Body Composition

1w ago
0:50
youtube.com

Unlock Blood Sugar Secrets Beyond A1C, Find Insulin Resistance

1w ago
0:28
youtube.com

Unlock Better Health Track Food & Glucose

1w ago
0:36
youtube.com

Understanding Stress Beyond Situational Factors

1w ago
0:34
youtube.com

Heal Your Metabolism Midlife Nuanced Approach

2w ago
1:39
youtube.com

Body Composition Scan Beyond Weight Loss for Health

2w ago
4:44
youtube.com

Breast Cancer Awareness: Help Us Support a Woman Newly Diagnosed

3w ago
57:23
youtube.com

Why Your Body Changes in Midlife: Hormones, Blood Sugar & Belly Fat

3w ago
0:29
youtube.com

Spirulina in the Morning, Chlorella at Night? How to Use Algae in Your Daily Routine

3w ago
0:39
youtube.com

Unlock Your Mitochondria: Catharine Arnston’s Secrets to Energy & Healthy Aging

3w ago
See all content